Solutions & Services
Therapeutic expertise
Why APICES
Rare disease trials are defined by scarcity. Patient populations are small, diagnoses are often delayed or fragmented, and clinical expertise is concentrated in a limited number of reference centers. In this context, feasibility is not a statistical exercise. It is a question of access, alignment, and timing.
APICES brings rare disease expertise grounded in studies where every patient matters. We understand how diagnostic pathways, referral patterns, and investigator networks shape what is realistically achievable. This insight informs study designs that reflect how patients are identified and followed in practice, rather than relying on theoretical prevalence or broad geographic expansion.
In rare disease development, design flexibility and early judgment are critical. Traditional study models often need to be adapted to reflect limited populations, heterogeneous disease presentation, and constrained site capacity. APICES supports sponsors at an early stage to evaluate alternatives, understand trade-offs, and select approaches that expert centers can execute.
The outcome is a study built around real patient access, focused site engagement, and execution strategies that prioritize feasibility over scale.
Immune Thrombocytopenia • Small Cell Lung Cancer • Haemophilia • Idiopathic Multicentric Castleman Disease • Growth Hormone Deficiency • Glioma • Mycosis Fungoides • Leukemia • Primary Membranous Nephropathy • Intra-axial Brain Tumour • Granulosa Cell Tumor • Pancreatic Cancer • Pulmonary Hypertension • Hypophosphataemia • Hyperphosphatemia • Cryopyrin-Associated Periodic Syndromes • Acromegaly • Amyloidosis • Bronchiolitis Obliterans • Cystic Fibrosis • Adrenal Insufficiency
Talk to our team about how execution realities may shape the feasibility and timelines of your rare disease study.
When moving from protocol to first European execution →
When scale, consistency, and delivery discipline matter →